Skip to main content

Glypican 3 Antibody (Codrituzumab) - Humanized

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28387

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # Codrituzumab

Concentration

LYOPH mg/ml

Product Specifications

Immunogen

GPC3 / Glypican-3

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Description

Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

Also known as 'codrituzumab'.

Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Scientific Data Images for Glypican 3 Antibody (Codrituzumab) - Humanized

Glypican 3 Antibody (Codrituzumab) - Humanized

Functional: Glypican 3 Antibody (Codrituzumab) - Humanized[NBP3-28387] -

Glypican 3 Antibody (Codrituzumab) - Humanized induced ADCC activity was evaluated using human GPC3 CHOS Cell. The max Lysis rate was approximately 30%.
Glypican 3 Antibody (Codrituzumab) - Humanized

Functional: Glypican 3 Antibody (Codrituzumab) - Humanized[NBP3-28387] -

The endocytosis ratio codrituzumab by HuH-7 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 40%at antibody concentration of 1 nM.
Glypican 3 Antibody (Codrituzumab) - Humanized

ELISA: Glypican 3 Antibody (Codrituzumab) - Humanized[NBP3-28387] -

Immobilized human GPC3, His Tag at 2 ug/mL can bind Glypican 3 Antibody (Codrituzumab) - Humanized, EC50=0.008741 ug/mL.

Applications for Glypican 3 Antibody (Codrituzumab) - Humanized

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: Glypican 3

The Glypican 3 (GPC3) gene encodes for a member of the glypican-related integral membrane proteoglycan family (GRIPS). Two isoforms of the protein exist, isoform 1 at a length of 580 amino acids long and 65 kDA while isoform 2 is 526 amino acids long at 59 kDA. The protein encoded by GPC3 is thought to prevent the dipeptidyl peptidase activity of DPP4 and may participate in the suppression and regulation of growth in the predominately mesodermal tissues and organs. The GPC3 gene participates in the Wnt signaling pathway, metabolism, and visual phototransduction through interactions with genes FGF2, WNT3A, WNT7B, BCAN, and BGN. GPC3 has been researched in various diseases such as paine syndrome, horner's sundrome, liver cirrhosis, simpson-golabi-behmel syndrome, germ cell tumors, wilms tumors, complex regional pain syndrome, and hepatocellulcar carcinoma.

Alternate Names

GPC3

Gene Symbol

GPC3

UniProt

Additional Glypican 3 Products

Product Documents for Glypican 3 Antibody (Codrituzumab) - Humanized

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Glypican 3 Antibody (Codrituzumab) - Humanized

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...